Related Experiment Videos
[Global analysis of data from studies with PDE1 alpha-cyslodextrin]
G Laurora1, G Belcaro, M R Cesarone
1Angiology and Vasc. Surgery, Clinical Trials Unit, Pierangeli Clinic, Pescara.
Insights
Prostaglandin E1 alpha-cyclodextrin (PGE1) treatment effectively improved outcomes in 595 patients with severe peripheral vascular disease, including those with critical limb ischemia and diabetes. The short-term protocol demonstrated significant efficacy with manageable side effects and cost-effectiveness.
Area of Science:
- Vascular Medicine
- Pharmacology
- Clinical Therapeutics
Context:
- Severe peripheral vascular disease (PVD) significantly impacts patient mobility and quality of life.
- Existing treatments for PVD often have limitations in efficacy and side effect profiles.
- Prostaglandin E1 (PGE1) alpha-cyclodextrin has been investigated for its therapeutic potential in PVD.
Purpose:
- To evaluate the efficacy and safety of Prostaglandin E1 alpha-cyclodextrin (PGE1) in a large cohort of patients with severe peripheral vascular disease.
- To assess treatment outcomes in distinct patient subgroups, including those with intermittent claudication, critical limb ischemia, and diabetes.
- To analyze the cost-effectiveness of the short-term PGE1 treatment protocol.
Summary:
- A total of 595 patients with severe PVD received PGE1 alpha-cyclodextrin treatment, with a majority undergoing a short-term protocol.
- Significant clinical improvement was observed in 78% of patients with intermittent claudication and 66% with critical limb ischemia.
- Diabetic patients with PVD also showed a 58% improvement rate, with a low incidence (5%) of clinically relevant side effects, mostly manageable.
Impact:
- PGE1 alpha-cyclodextrin treatment offers a safe and effective therapeutic option for patients suffering from severe peripheral vascular disease.
- The short-term protocol is highlighted as particularly cost-effective, suggesting potential for wider clinical adoption.
- This study supports PGE1 alpha-cyclodextrin as a valuable addition to the management of complex vascular conditions, improving patient outcomes.
Background:
A group of patients with severe peripheral vascular disease has been treated with PGE1 alpha-ciclodestrina (as reported in the previous 9 articles) including 595 patients (mean age 64.52 +/- 12; 307 with intermittent claudication and 237 with critical limb ischemia, rest pain and gangrene). Also 51 diabetics were studied and treated (25% with claudication and the remaining group with critical ischemia and/or neuropathy). The mean dosage administered in most patients (83% were treated with the short-term protocol) had been 20 + 40 micrograms on the first day and 60 + 40 micrograms on the second day.
Methods:
Subjects had been treated on average 2.6 times (cycles of short term treatment); 37% of patients had received at least 3 cycles of short term treatment. Clinically relevant side effects have been observed in 30 patients (5% of the 595 treated patients). Temporary suspension of treatment has reduced/abolished side effects in 18 out of 30 patients and only in 5 patients (0.8%) therapy had to be suspended. Clinical improvement was evaluated according to subjective improvement, objective improvement (as defined by the treating physician/surgeon) and one or more physiological parameters (flux, flow, treadmill test). Among patients with intermittent claudication (only considered endpoint was walking distance) 78% was significantly improved. In patients with critical ischemia (endpoints were pain control, decrease of ischemic areas and perfusion improvement, objectively measured) 66% of patients improved. In diabetics (including both claudicants and subjects with critical ischemia) 58% improved.
Conclusions:
Global analysis of the previous 9 studies indicates that PGE1 alpha-ciclodestrina treatment is effective, there are few and controllable (in most patients) side effects and the treatment (particularly the short term protocol) is very cost effective.